Ovarian Cancer | Clinical

Neoadjuvant or Adjuvant Ruxolitinib Plus Chemotherapy Feasible in Ovarian Cancer

June 07, 2022

Ruxolitinib and chemotherapy appeared to boost progression-free survival in patients with stage III and IV ovarian cancer when given before or after surgery.

Frontline Bevacizumab Beneficial for Ovarian Clear Cell Carcinoma, Retrospective Analysis Shows

June 06, 2022

Bevacizumab improved progression-free survival and overall survival when added to frontline chemotherapy in patients with advanced ovarian clear cell carcinoma, according to a retrospective analysis of patients treated in Japan from 2008 to 2018.

PFS Improvement With Frontline Rucaparib Maintenance Shown in Ovarian Cancer, Regardless of HRD Status

June 06, 2022

Patients with platinum-sensitive ovarian cancer treated with maintenance rucaparib in the ATHENA-MONO trial showed a significant improvement in progression-free survival when compared with placebo in the first-line setting, regardless of HRD status.

FDA Grants Priority Review to Mirvetuximab Soravtansine in FRα-High Platinum-Resistant Ovarian Cancer

May 23, 2022

Priority review to a biologics license application has been granted by the FDA for mirvetuximab soravtansine to treat patients with folate receptor alpha-high platinum-resistant ovarian cancer.

Investigators Hope Oregovomab Combo Will Show Benefit in Advanced Epithelial Ovarian Cancer

May 19, 2022

A new murine monoclonal antibody B43.12 is under investigation in combination with paclitaxel and carboplatin as a treatment option for patients with advanced epithelial ovarian cancer.

First-line Niraparib Improves PFS in Ovarian Cancer

May 18, 2022

An individualized starting dose of niraparib, determined by weight and platelet count, continued to demonstrate a clinical meaningful improvement in progression-free survival in newly diagnosed ovarian cancer in the first-line maintenance setting, regardless of biomarker status,

Prognostic Factors to Watch Out for in Patients With Ovarian Cancer

May 17, 2022

Eric Pujade-Lauraine, MD, PhD, discusses the prognostic factors researchers are looking for when testing patients with ovarian cancer.

World Ovarian Cancer Day: A Time of Great Innovation and Advancement

May 08, 2022

Barbara Buttin, MD, covers the past and present standards of care, as well as upcoming therapeutic options, for World Ovarian Cancer Day.

Krivak Breaks Down Data for First-Line Maintenance Therapy Options in Advanced Ovarian Cancer

April 27, 2022

During a Targeted Oncology case-based roundtable event, Thomas C. Krivak, MD, discussed the results of studies of PARP inhibition for patients with advanced ovarian cancer.

FDA Grants FTD to Ofra-Vec Plus Paclitaxel for Platinum-Resistant Ovarian Cancer

April 26, 2022

The FDA has granted fast track designation to ofranergene obadenovec in combination with paclitaxel for the treatment of platinum-resistant ovarian cancer. The agent is under investigation in the phase 3 OVAL study.